Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
Price trading | mfayman | investorshub | 09/22/2023 10:19:08 AM |
Price now | mfayman | investorshub | 09/22/2023 10:12:41 AM |
just the news we needed | mfayman | investorshub | 09/22/2023 9:33:36 AM |
$OKYO just the news we needed | mfayman | investorshub | 09/22/2023 9:22:37 AM |
Price gaining | Boris the Spider | investorshub | 09/22/2023 9:08:00 AM |
$OKYO The gaining | Sirpeter | investorshub | 09/22/2023 8:49:59 AM |
$OKYO are we finally gonna see some action | StocksNcash | investorshub | 09/22/2023 8:10:13 AM |
is it bear time? Or do we go bull? | ErnieBilco | investorshub | 09/22/2023 7:38:12 AM |
Price gaining | StocksNcash | investorshub | 09/22/2023 7:22:24 AM |
Price now | mfayman | investorshub | 09/22/2023 5:52:26 AM |
we got news | mfayman | investorshub | 09/22/2023 4:15:31 AM |
bears are running | Count Crypto | investorshub | 09/22/2023 2:23:35 AM |
and the shorts continue | Ryguy008 | investorshub | 09/22/2023 2:16:43 AM |
got some short data | Count Crypto | investorshub | 09/21/2023 11:58:45 PM |
$OKYO short squeeze article | Sirpeter | investorshub | 09/21/2023 11:24:19 PM |
$OKYO bears and bulls | mfayman | investorshub | 09/21/2023 11:11:18 PM |
$OKYO Price trading last trade up | Count Crypto | investorshub | 09/21/2023 8:33:29 PM |
$OKYO Price gaining | mfayman | investorshub | 09/21/2023 2:59:35 PM |
The trading last trade up | Sirpeter | investorshub | 09/21/2023 2:59:27 PM |
Price trading | Ryguy008 | investorshub | 09/21/2023 12:45:35 PM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...